Statins as novel immunomodulators: From cell to potential clinical benefit

Thrombosis and Haemostasis

Volumn 90, Issue 4, 2003, Pages 607-610

  Mach, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Atherosclerosis; Cytokines; Immunity (auto ); Inflammatory mediators; Lipid mediators

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CYTOKINE; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; ISOPRENOID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; RECOMBINANT GAMMA INTERFERON; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CELL FUNCTION; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COMPETITIVE INHIBITION; CYTOKINE RELEASE; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GRAFT REJECTION; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; METABOLIC REGULATION; MULTIPLE SCLEROSIS; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SURVIVAL; VASCULAR DISEASE;

EID: 0142092591     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-04-0249     Document Type: Review

References (32)

1. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4: 1241-3.
2. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
3. Glass CK, Witztum JL. Atherosclerosis: The road ahead. Cell 2001; 104: 503-16.
4. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
5. Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247: 349-58.
6. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-13.
7. Plana JC, Jones PH. The use of statins in acute coronary syndromes: The mechanisms behind the outcomes. Curr Atheroscler Rep 2001; 3: 355-64.
8. Gotto AM, Jr. Statin therapy: Where are we? Where do we go next? Am J Cardiol 2001; 87: 13B-18B.
9. Gotto AM, Jr., Grundy SM. Lowering LDL cholesterol: Questions from recent meta-analyses and subset analyses of clinical trial. Data Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. Circulation 1999; 99: E1-7.
10. Corsini A, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-28.
11. Bellosta S, Ferri N, Bernini F, et al. Nonlipid-related effects of statins. Ann Med 2000; 32: 164-76.
12. Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep 2000; 2: 208-17.
13. Kwak BR, Mach F. Statins inhibit leukocyte recruitment: New evidence for their anti-inflammatory properties. Arterioscler Thromb Vasc Biol 2001; 21: 1256-8.
14. Gotto AM, Jr. Farmer JA. Pleiotropic effects of statins: Do they matter? Curr Opin Lipidol 2001; 12: 391-4.
15. Casey PJ. Protein lipidation in cell signaling. Science 1995; 268: 221-5.
16. Maltese WA, Sheridan KM, Repko EM, et al. Post-translational modification of low molecular mass GTP-binding proteins by isoprenoid. J Biol Chem 1990; 265: 2148-55.
17. Veillard NR, Mach F. Statin: The new aspirin? Cell Mol Life Sci 2002; 59: 1771-86.
18. Kobashigawa JA, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-7.
19. Wenke K, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial. Circulation 1997; 96: 1398-1402.
20. Steimle V, Otten LA, Zufferey M, et al. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75: 135-46.
21. Steimle V, Siegrist CA, Mottet A, et al. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994; 265: 106-9.
22. Muhlethaler-Mottet A, Otten LA, Steimle V, et al. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997; 16: 2851-60.
23. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-402.
24. Kwak B, Mulhaupt F, Veillard N, et al. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001; 131: 41-6.
25. Palinski W. Immunomodulation: A new role for statins? Nat Med 2000; 6: 1311-12.
26. Sadeghi MM, Tiglio A, Sadigh K, et al. Inhibition of interferon-gamma-mediated of microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 2001; 71: 1262-8.
27. Youssef S, Stüve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84.
28. Leung BP, Satta N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-30.
29. Mulhaupt F, Kwak B, Veillard N, et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in atheroma-associated cells. Possible implications for atherogenesis and transplantation. Circulation 2001; 104: II212.
30. Wagner AH, Gebauer M, Güldenzoph B, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 1784-9.
31. Schönbeck U, Gerdes N, Varo N, et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002; 106: 2888-93.
32. Leung BP, Satta N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-30.